Results 151 to 160 of about 2,829,238 (289)
Artificial Intelligence in Scientific Writing: A Deuteragonistic Role? [PDF]
Wohlfarth B, Streit SR, Guttormsen S.
europepmc +1 more source
THE KEYS TO PREPARING SUCCESSFUL RESEARCH GRANT PROPOSALS [PDF]
This article seeks to demystify the competitive grant recommendation process of scientific peer review panels. The National Research Initiative Competitive Grants Program (NRICGP) administered by the U.S.
Marchant, Mary A.
core +1 more source
Liquid biopsy enables minimally invasive, real‐time molecular profiling through analysis of circulating biomarkers in biological fluids. This Perspective highlights the importance of training pathologists through integrative educational programs, such as the European Masters in Molecular Pathology, to ensure effective and equitable implementation of ...
Marius Ilié +13 more
wiley +1 more source
Editorial: Nutritional therapy along the continuum of care
Barbara Troesch, Matthias Pirlich
doaj +1 more source
Marked reduction in hallucination rates with GPT-5: A positive development for medical and scientific writing. [PDF]
Polat S +5 more
europepmc +1 more source
Correspondence: ChatGPT and scientific writing. [PDF]
Mungmunpuntipantip R +2 more
europepmc +1 more source
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice +16 more
wiley +1 more source
AI in scientific writing and publishing: A call for critical engagement. [PDF]
Frangou S, Volpe U, Fiorillo A.
europepmc +1 more source
Ethnopsychopharmacology: Clinical and scientific writing pearls. [PDF]
Leung JG.
europepmc +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source

